Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4673-4680

  Safronetz, David ^a   Falzarano, Darryl ^a   Scott, Dana P ^a   Furuta, Yousuke ^b   Feldmann, Heinz ^a   Gowen, Brian B ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b TOYAMA CHEMICAL CO LTD   (Japan)

^c UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; RIBAVIRIN; VIRUS ANTIGEN; VIRUS RNA;

ANDES VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; FEMALE; HAMSTER; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SIN NOMBRE VIRUS; SURVIVAL RATE; TITRIMETRY;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CRICETINAE; FEMALE; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; PYRAZINES; SIN NOMBRE VIRUS; VIRUS REPLICATION;

EID: 84884268745     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00886-13     Document Type: Article

References (35)

1. ICTV. July 2012, posting date. Virus taxonomy. http://ictvonline.org /virusTaxonomy.asp.
2. Jonsson CB, Figueiredo LT, Vapalahti O. 2010. A global perspective on hantavirus ecology, epidemiology, and disease. Clin. Microbiol. Rev. 23: 412-441.
3. Macneil A, Nichol ST, Spiropoulou CF. 2011. Hantavirus pulmonary syndrome. Virus Res. 162:138-147.
4. Webster D, Lee B, Joffe A, Sligl W, Dick D, Grolla A, Feldmann H, Yacoub W, Grimsrud K, Safronetz D, Lindsay R. 2007. Cluster of cases of hantavirus pulmonary syndrome in Alberta, Canada. Am. J. Trop. Med. Hyg. 77:914-918.
5. Centers for Disease Control and Prevention. 2012. Hantavirus pulmonary syndrome in visitors to a national park-Yosemite Valley, California, 2012. MMWR Morb. Mortal. Wkly. Rep. 61:952.
6. MacNeil A, Ksiazek TG, Rollin PE. 2011. Hantavirus pulmonary syndrome, United States, 1993-2009. Emerg. Infect. Dis. 17:1195-1201.
7. Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, LeDuc JW, Zheng ZM, Meegan JM, Wang QN, Oland DD, Gui XE, Gibbs PH, Yuan GH, Zhang TM. 1991. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164:1119-1127.
8. Rusnak JM, Byrne WR, Chung KN, Gibbs PH, Kim TT, Boudreau EF, Cosgriff T, Pittman P, Kim KY, Erlichman MS, Rezvani DF, Huggins JW. 2009. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res. 81:68-76.
9. Safronetz D, Haddock E, Feldmann F, Ebihara H, Feldmann H. 2011. In vitro and in vivo activity of ribavirin against Andes virus infection. PLoS One 6:e23560. doi:10.1371/journal.pone.0023560.
10. Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, Ksiazek TG, Koster FT, Baum KF, Rollin PE, Pavia AT, Holman RC, Christenson JC, Rubin PJ, Behrman RE, Bell LJ, Simpson GL, Sadek RF. 1999. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir. Ther. 4:211-219.
11. Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, Levy H, Koster FT, Baum K, Lindemulder A, Wang W, Riser L, Fernandez H, Whitley RJ. 2004. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 39:1307-1313.
12. Jonsson CB, Hooper J, Mertz G. 2008. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 78:162-169.
13. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51:845-851.
14. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. U. S. A. 107:882-887.
15. Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV. 2010. In vitro antiviral activity of favipiravir (T-705) against drugresistant influenza and 2009 A(H1N1) viruses. Antimicrob. Agents Chemother. 54:2517-2524.
16. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, Christensen AJ, Furuta Y. 2008. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res. 80:377-379.
17. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MS, Neyts J. 2012. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem. Biophys. Res. Commun. 424:777-780.
18. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51:3168-3176.
19. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, Gowen BB. 2011. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 55:782-787.
20. Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB. 2011. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLoS Negl. Trop. Dis. 5:e1342. doi:10.1371/journal.pntd.0001342.
21. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82:95-102.
22. Buys KK, Jung KH, Smee DF, Furuta Y, Gowen BB. 2011. Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antivir. Chem. Chemother. 21:193-200.
23. Safronetz D, Hegde NR, Ebihara H, Denton M, Kobinger GP, St Jeor S, Feldmann H, Johnson DC. 2009. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J. Virol. 83:7285-7295.
24. Safronetz D, Prescott J, Haddock E, Scott DP, Feldmann H, Ebihara H. 2013. Hamster-adapted Sin Nombre virus causes disseminated infection and efficiently replicates in pulmonary endothelial cells without signs of disease. J. Virol. 87:4778-4782.
25. Feldmann H, Sanchez A, Morzunov S, Spiropoulou CF, Rollin PE, Ksiazek TG, Peters CJ, Nichol ST. 1993. Utilization of autopsy RNA for the synthesis of the nucleocapsid antigen of a newly recognized virus associated with hantavirus pulmonary syndrome. Virus Res. 30:351-367.
26. Botten J, Mirowsky K, Kusewitt D, Bharadwaj M, Yee J, Ricci R, Feddersen RM, Hjelle B. 2000. Experimental infection model for Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus). Proc. Natl. Acad. Sci. U. S. A. 97:10578-10583.
27. Medina RA, Mirowsky-Garcia K, Hutt J, Hjelle B. 2007. Ribavirin, human convalescent plasma and anti-3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model. J. Gen. Virol. 88:493-505.
28. Schmaljohn CS. 2012. Vaccines for hantaviruses: progress and issues. Expert Rev. Vaccines 11:511-513.
29. Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. 2003. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virusMgenome segment-based DNA vaccine. J. Virol. 77:9894-9905.
30. Hooper JW, Ferro AM, Wahl-Jensen V. 2008. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J. Virol. 82:1332-1338.
31. Brocato R, Josleyn M, Ballantyne J, Vial P, Hooper JW. 2012. DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). PLoS One 7:e35996. doi:10.1371/journal.pone.0035996.
32. Safronetz D, Zivcec M, Lacasse R, Feldmann F, Rosenke R, Long D, Haddock E, Brining D, Gardner D, Feldmann H, Ebihara H. 2011. Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus. PLoS Pathog. 7:e1002426. doi:10.1371/journal .ppat.1002426.
33. Safronetz D, Ebihara H, Feldmann H, Hooper JW. 2012. The Syrian hamster model of hantavirus pulmonary syndrome. Antiviral Res. 95: 282-292.
34. Reagan-Shaw S, Nihal M, Ahmad N. 2008. Dose translation from animal to human studies revisited. FASEB J. 22:659-661.
35. FujiFilm Pharmaceuticals U.S.A., Inc. 15 November 2012, revision date. Dose-finding study of favipiravir in the treatment of uncomplicated influenza. http://clinicaltrials.gov/show/NCT01068912.